SCHEMBL1892009

SCHEMBL1892009

CC(C)(C)OC(=O)N1CCC[C@H]1c1nc(-c2cnc(-c3cnc4cc(-c5cnc([C@@H]6CCCN6C(=O)OC(C)(C)C)n5COCC[Si](C)(C)C)ccc4n3)nc2)c[nH]1

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 1/20 0.34
HPGDS O60760 3/20 0.33
GPR119 Q8TDV5 3/20 0.32
DGAT1 O75907 2/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
MEN1 O00255 2/20 0.31
LMNA P02545 2/20 0.31
TSHR P16473 2/20 0.31
KMT2A Q03164 2/20 0.31
ALDH1A1 P00352 1/20 0.31
ALOX5AP P20292 1/20 0.31
FEN1 P39748 1/20 0.31
MAPT P10636 1/20 0.30
HTT P42858 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
POLB P06746 1/20 0.30
F11 P03951 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL932641 0.98 HPGDS (0.33) CHEK2HPGDSGPR119L3MBTL1MEN1
SCHEMBL1889043 0.94 DGAT1 (0.34) CHEK2HPGDSGPR119DGAT1L3MBTL1
SCHEMBL933407 0.92 DGAT1 (0.32) CHEK2HPGDSGPR119DGAT1L3MBTL1
SCHEMBL12661193 0.91 CHEK2 (0.34) CHEK2HPGDSGPR119DGAT1L3MBTL1
SCHEMBL1888132 0.89 HPGDS (0.34) CHEK2HPGDSGPR119DGAT1MEN1
SCHEMBL1892185 0.89 CHEK2 (0.32) CHEK2HPGDSGPR119DGAT1L3MBTL1
SCHEMBL933689 0.89 HPGDS (0.33) CHEK2HPGDSGPR119DGAT1L3MBTL1
SCHEMBL1892016 0.87 CHEK2 (0.32) CHEK2GPR119
SCHEMBL933621 0.87 HPGDS (0.34) CHEK2HPGDSGPR119DGAT1
SCHEMBL12661154 0.87 CHEK2 (0.34) CHEK2GPR119DGAT1L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110112100-A1 Hepatitis C Virus Inhibitors PFIZER INC. 2011-05-12 US disclosed
US-20110112100-A1 Hepatitis C Virus Inhibitors PFIZER INC. 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112100-A1 Hepatitis C Virus Inhibitors HAVCR2, SLC10A1, HCCS CHEK2 3724/4885HPGDS 1869/4885GPR119 2249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.